Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Hannah Johnson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, United S…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Protein Phosphatase 2, Fluorouracil, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NIGMS NIH HHS, NIA NIH HHS, Penn State College of Medicine.
Abstract (Originalsprache)
A series of compounds were designed utilizing molecular modeling and fragment-based design based upon the known protein phosphatase 2A (PP2A) activators, NSC49L and iHAP1, and evaluated for their ability to inhibit the viability of colorectal cancer (CRC) and folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX)-resistant CRC cells. PPA24 (19a) was identified as the most cytotoxic compound with IC50 values in the range of 2.36-6.75 μM in CRC and FOLFOX-resistant CRC cell lines. It stimulated PP2A activity to a greater extent, displayed lower binding energies through molecular docking, and showed higher binding affinity through surface plasmon resonance for PP2A catalytic subunit α than the known PP2A activators. PPA24 dose-dependently induced apoptosis and oxidative stress, decreased the level of c-Myc expression, and synergistically potentiated cytotoxicity when combined with gemcitabine and cisplatin. Furthermore, a PPA24-encapsulated nanoformulation significantly inhibited the growth of CRC xenografts without systemic toxicities. Together, these results signify the potential of PPA24 as a novel PP2A activator and a prospective therapeutic for CRC and FOLFOX-resistant CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Penn State Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, United States.
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Drive, Gainesville, Florida 32610, United States.
- Department of Anatomy and Cell Biology, College of Medicine, University of Florida, 1200 Newell Drive, Gainesville, Florida 32610, United States.
ORCID-Profile: Hannah Johnson, Asif Raza, Congzhou M Sha, Jian Wang, Nikolay V Dokholyan, Arun K Sharma
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- Penn State College of Medicine
- Penn State Hershey Cancer Institute
- PA Tobacco Settlement Fund
Zitieren
APA
Johnson, H., Singh, A., Raza, A., Sha, C. M., Wang, J., Gowda, K., Shen, Z., Nair, H., Li, C., Dokholyan, N. V., Narayan, S., & Sharma, A. K. (2024). Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01077
Vancouver
Johnson H, Singh A, Raza A, Sha CM, Wang J, Gowda K, et al. Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01077
BibTeX
@article{Johnson2024,
author = {Johnson, Hannah and Singh, Amandeep and Raza, Asif and Sha, Congzhou M and Wang, Jian and Gowda, Krishne and Shen, Zhihang and Nair, Haritha and Li, Chenglong and Dokholyan, Nikolay V and Narayan, Satya and Sharma, Arun K},
title = {Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01077}
}
EUVIMED